The serotonergic system in Parkinson's disease
- PMID: 21878363
- DOI: 10.1016/j.pneurobio.2011.08.004
The serotonergic system in Parkinson's disease
Abstract
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding.
Copyright © 2011. Published by Elsevier Ltd.
Similar articles
-
The serotonergic system in motor and non-motor manifestations of Parkinson's disease.Exp Brain Res. 2013 Oct;230(4):463-76. doi: 10.1007/s00221-013-3621-2. Epub 2013 Jun 28. Exp Brain Res. 2013. PMID: 23811734 Review.
-
Serotonergic neurotransmission in early Parkinson's disease: a pilot study to assess implications for depression in this disorder.World J Biol Psychiatry. 2010 Sep;11(6):781-7. doi: 10.3109/15622975.2010.491127. World J Biol Psychiatry. 2010. PMID: 20586535
-
Serotonin and Parkinson's disease: On movement, mood, and madness.Mov Disord. 2009 Jul 15;24(9):1255-66. doi: 10.1002/mds.22473. Mov Disord. 2009. PMID: 19412960 Review.
-
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Prog Brain Res. 2008. PMID: 18772047 Review.
-
Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.Prog Brain Res. 2008;172:423-63. doi: 10.1016/S0079-6123(08)00921-7. Prog Brain Res. 2008. PMID: 18772045 Review.
Cited by
-
Impact of Serotonergic 5HT1A and 5HT2A Receptor Activation on the Respiratory Response to Hypercapnia in a Rat Model of Parkinson's Disease.Int J Mol Sci. 2024 Apr 17;25(8):4403. doi: 10.3390/ijms25084403. Int J Mol Sci. 2024. PMID: 38673988 Free PMC article.
-
Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease.J Neurol. 2024 Apr;271(4):1959-1972. doi: 10.1007/s00415-023-12122-1. Epub 2023 Dec 27. J Neurol. 2024. PMID: 38151574
-
Updated Parkinson's disease motor subtypes classification and correlation to cerebrospinal homovanillic acid and 5-hydroxyindoleacetic acid levels.Clin Park Relat Disord. 2023 Jan 27;8:100187. doi: 10.1016/j.prdoa.2023.100187. eCollection 2023. Clin Park Relat Disord. 2023. PMID: 36793590 Free PMC article.
-
Common and unique dysconnectivity profiles of dorsal and median raphe in Parkinson's disease.Hum Brain Mapp. 2023 Feb 15;44(3):1070-1078. doi: 10.1002/hbm.26139. Epub 2022 Nov 5. Hum Brain Mapp. 2023. PMID: 36334274 Free PMC article.
-
The pathobiological basis of depression in Parkinson disease: challenges and outlooks.J Neural Transm (Vienna). 2022 Dec;129(12):1397-1418. doi: 10.1007/s00702-022-02559-5. Epub 2022 Nov 2. J Neural Transm (Vienna). 2022. PMID: 36322206 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
